Vanguard Group’s Cue Health HLTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-3,884,285
Closed -$733K – 4466
2024
Q1
$733K Hold
3,884,285
– – ﹤0.01% 3904
2023
Q4
$631K Hold
3,884,285
– – ﹤0.01% 3964
2023
Q3
$1.72M Hold
3,884,285
– – ﹤0.01% 3641
2023
Q2
$1.43M Sell
3,884,285
-461,854
-11% -$394K ﹤0.01% 3780
2023
Q1
$7.91M Buy
4,346,139
+26,531
+0.6% +$57.7K ﹤0.01% 3069
2022
Q4
$8.94M Buy
4,319,608
+282,633
+7% +$893K ﹤0.01% 3001
2022
Q3
$12.2M Buy
4,036,975
+1,327,510
+49% +$4.71M ﹤0.01% 2858
2022
Q2
$8.67M Buy
2,709,465
+2,522,091
+1,346% +$13.7M ﹤0.01% 3071
2022
Q1
$1.21M Buy
187,374
+2,117
+1% +$19.1K ﹤0.01% 4150
2021
Q4
$2.48M Buy
185,257
+60,257
+48% +$663K ﹤0.01% 3962
2021
Q3
$1.48M Buy
+125,000
New +$1.97M ﹤0.01% 4151

Other funds holding HLTH

Vanguard Group's HLTH Position: Q2 2024 in Review

Vanguard Group sold out of Cue Health (HLTH) in Q2 2024, closing a stake of 3,884,285 shares — an estimated $733K sold.

Vanguard Group first reported a position in HLTH in Q3 2021 and held it in 11 quarters. The position peaked at $12.2M in Q3 2022. 9 funds tracked by Wall St. Rank hold HLTH as of Q2 2024.

  • Vanguard Group reported no remaining Cue Health position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 3,884,285 Cue Health shares in Q2 2024, an estimated $733K.
  • Vanguard Group first reported a position in Cue Health in Q3 2021 and held it in 11 quarters.
  • Vanguard Group's Cue Health position peaked at $12.2M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Cue Health as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.